Niagen Bioscience Inc (NASDAQ:NAGE) (formerly ChromaDex Corp), which specialises in NAD+ (nicotinamide adenine dinucleotide) science and healthy-ageing research, announced on Thursday that it has secured US Patent 12,252,506, covering the composition of matter for various nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate.

The patent, exclusively licensed from Queen's University Belfast, grants Niagen Bioscience exclusive rights to these salt forms and other NR derivatives, reinforcing its leadership in the NAD+ precursor market.

Rob Fried, CEO of Niagen Bioscience, said that the composition of matter patent offers strong intellectual property protection, preventing any company from producing these NR salt forms at a commercial scale without infringing. The patent covers newer NR salt forms as well as carboxylic acid, dicarboxylic acid, aminodicarboxylic acid, phosphate, sulfate, carbonate and carbamate salts, providing protection for use as nutritional supplements.

Part of the 'Methods of Preparing Nicotinamide Riboside and Derivatives' patent family, this patent ensures protection for various NR and NR triacetate salt forms until 2034.